The treatment of renal cell carcinoma has long been dominated by targeted treatments, including mTOR and angiogenesis inhibitors. However, the introduction of immune checkpoint inhibitors has diversified treatment options. The treatment landscape for renal cell carcinoma is rapidly moving toward combination combinatorial approaches, as witnessed by the approvals of Lenvima/Kisplyx (Eisai) plus Afinitor (Novartis) in 2016, Opdivo plus Yervoy (Bristol-Myers Squibb/Ono Pharmaceutical) in 2018, and Keytruda (Merck & Co.) plus Inlyta (Pfizer) in 2019. As combination regimens experience uptake in the larger and more commercially lucrative first-line advanced setting, drug developers should gain an understanding of the key drivers and obstacles to maximize uptake.
- What are the drug-treatment rates across clinically and commercially relevant renal cell carcinoma patient populations?
- How are the new drug entrants performing in the face of existing small-molecule TKIs such as Votrient and Sutent for advanced disease?
- What is the uptake of Opdivo plus Yervoy in previously untreated intermediate- or poor-risk advanced renal cell carcinoma, according to U.S. medical oncologists?
- What factors drive or constrain the prescribing habits of U.S. medical oncologists?
Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that marketers can create specific messaging around these treatment dynamics to more effectively increase or defend their market position.
Geographies: United States
Primary Research: Survey of 100 medical oncologists in the United States
Key Ddrugs Ccovered: Opdivo, Yervoy, Cabometyx, Sutent, Votrient, Inlyta, Afinitor, Lenvima